Zean Zhao

No. 2004 Hongli Road
Shenzhen, 518028, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Isobavachin Attenuates Renal and Cardiac Injury in Chronic Hyperuricemia via Modulation of NF-κB and NLRP3 Signaling Pathways.

Isobavachin Attenuates Renal and Cardiac Injury in Chronic Hyperuricemia via Modulation of NF-κB and NLRP3 Signaling Pathways.

Journal: Journal of biochemical and molecular toxicology

Published: March 28, 2026

Integrated aptamer-based DNAzyme motor with pattern recognition for discriminative intracellular uric acid biosensing and high-throughput GLUT9 inhibitor discovery.

Integrated aptamer-based DNAzyme motor with pattern recognition for discriminative intracellular uric acid biosensing and high-throughput GLUT9 inhibitor discovery.

Journal: Biosensors & bioelectronics

Published: September 24, 2025

5-O-Methylvisammioside, a novel inhibitor of CNT2, improves hyperuricemia by inhibiting intestinal purine nucleoside absorption with a safe profile.

5-O-Methylvisammioside, a novel inhibitor of CNT2, improves hyperuricemia by inhibiting intestinal purine nucleoside absorption with a safe profile.

Journal: Biochemical pharmacology

Published: May 23, 2025

Recent Progress in the Development of Glucose Transporter (GLUT) Inhibitors.

Recent Progress in the Development of Glucose Transporter (GLUT) Inhibitors.

Journal: Journal of medicinal chemistry

Published: January 02, 2025

A novel method for screening antihyperuricemic drugs by combining aptamer sensor array, exonuclease III-DNA walker and linear discriminant analysis.

A novel method for screening antihyperuricemic drugs by combining aptamer sensor array, exonuclease III-DNA walker and linear discriminant analysis.

Journal: Journal of pharmaceutical analysis

Published: November 18, 2024

Recent Progress and Future Perspectives on Anti-Hyperuricemic Agents.

Recent Progress and Future Perspectives on Anti-Hyperuricemic Agents.

Journal: Journal of medicinal chemistry

Published: November 08, 2024

Discovery of cyanidin-3-O-galactoside as a novel CNT2 inhibitor for the treatment of hyperuricemia.

Discovery of cyanidin-3-O-galactoside as a novel CNT2 inhibitor for the treatment of hyperuricemia.

Journal: Bioorganic chemistry

Published: October 15, 2024

Discovery of multi-target anti-gout agents from Eurycoma longifolia Jack through phenotypic screening and structural optimization.

Discovery of multi-target anti-gout agents from Eurycoma longifolia Jack through phenotypic screening and structural optimization.

Journal: Nature communications

Published: July 31, 2024

Design, synthesis and bioactivity evaluation of isobavachin derivatives as hURAT1 inhibitors for hyperuricemia agents.

Design, synthesis and bioactivity evaluation of isobavachin derivatives as hURAT1 inhibitors for hyperuricemia agents.

Journal: European journal of medicinal chemistry

Published: June 26, 2024

Piperine Improves Hyperuricemic Nephropathy by Inhibiting URAT1/GLUT9 and the AKT-mTOR Pathway.

Piperine Improves Hyperuricemic Nephropathy by Inhibiting URAT1/GLUT9 and the AKT-mTOR Pathway.

Journal: Journal of agricultural and food chemistry

Published: March 18, 2024

Discovery of digallic acid as XOD/URAT1 dual target inhibitor for the treatment of hyperuricemia.

Discovery of digallic acid as XOD/URAT1 dual target inhibitor for the treatment of hyperuricemia.

Journal: Bioorganic chemistry

Published: March 03, 2024

Discovery and Characterization of Moracin C as an Anti-Gouty Arthritis/Hyperuricemia Candidate by Docking-Based Virtual Screening and Pharmacological Evaluation.

Discovery and Characterization of Moracin C as an Anti-Gouty Arthritis/Hyperuricemia Candidate by Docking-Based Virtual Screening and Pharmacological Evaluation.

Journal: Journal of natural products

Published: August 25, 2023

Showing 1-12 of 23

Last Updated: 09/26/2026